UK markets closed
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • FTSE 250

    22,336.10
    +266.79 (+1.21%)
     
  • AIM

    1,236.38
    +11.54 (+0.94%)
     
  • GBP/EUR

    1.1602
    -0.0025 (-0.21%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.36%)
     
  • BTC-GBP

    35,077.87
    -154.55 (-0.44%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • DOW

    34,382.13
    +360.68 (+1.06%)
     
  • CRUDE OIL

    65.51
    +1.69 (+2.65%)
     
  • GOLD FUTURES

    1,844.00
    +20.00 (+1.10%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     
  • HANG SENG

    28,027.57
    +308.90 (+1.11%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • CAC 40

    6,385.14
    +96.81 (+1.54%)
     

Global Antibody Purification Services Market by Company Size, Type of Antibody, Purification Method, End User and by Key Geographical Regions, 2021-2030

ReportLinker
·9-min read

INTRODUCTION Orthoclone OKT3® was the first monoclonal antibody-based drug (approved in 1986). As of today, more than 100 such products are available for therapeutic use across different geographies.

New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Antibody Purification Services Market by Company Size, Type of Antibody, Purification Method, End User and by Key Geographical Regions, 2021-2030" - https://www.reportlinker.com/p06064559/?utm_source=GNW
Recently, Margenza™ (December 2020) , Danyelza® (November 2020) , Adakveo® (November 2019) , Beovu® (October 2019) , SKYRIZI™ (April 2019) and EVENITY™ (April 2019) , were approved by the USFDA. Owing to their specificity for a target biomolecule (antigen) and favorable safety profile (compared to small molecule drugs), antibody-based interventions presently make up the largest class of biologic drugs. This trend is unlikely to change as multiple advanced variants of these drugs, such as bispecific antibodies and antibody fragments-based products, have been developed and several pharmacological leads based on these relatively novel constructs, are under evaluation. However, as is the case with all biologics, the production of antibodies is also a complex process. Specifically, antibody purification, which is one of the most crucial steps downstream of the manufacturing process, is a cost intensive operation. The investment of both effort and capital at this stage of production is justified because any impurity, or unwanted antibody molecule, poses a serious threat to not only therapeutic efficacy but also to the safety of patients. A variety of physiochemical approaches, including ammonium sulphate precipitation, hydrophobic interaction chromatography, ion-exchange chromatography and size exclusion chromatography techniques, are used to purify antibodies.

With the surge in demand for antibodies across research, diagnostic and therapeutic applications, there is now an urgent, parallel need to optimize production throughput. In this context, the purification aspect needs to be handled with extra caution, considering the dangers associated with contaminated medical products. Owing to prohibitive capital investments on purification infrastructure and the required expertise, not all therapy developers are able to establish in-house capabilities, especially at the larger (clinical and commercial) scales. Outsourcing is, therefore, a widely used operational model in this industry. The antibody purification services market today has evolved into a competitive domain, featuring the presence of start-ups, mid-sized companies and several established firms, some of which claim to offer end-to-end downstream processing solutions, as well. Moreover, such service-focused companies generally ensure that they have the latest upgrades in equipment and infrastructure, in order to differentiate themselves from the contemporary competition. Given the growing trend of outsourcing in the healthcare industry and the ongoing efforts of service providers to further improve / expand their respective portfolios, we believe the antibody purification services market is likely to evolve at a steady pace, till 2030.

SCOPE OF THE REPORT
The "Global Antibody Purification Services Market, 2020-2030" report features an extensive study on the current market landscape, offering an informed opinion on the future opportunities in this industry, over the next ten years. The study underlines an in-depth analysis of the purification services for antibodies offered by service providers, which are intended for use in various R&D and / or therapeutic purposes. In addition to other elements, it includes:
A detailed review of the overall landscape of the antibody purification services market, highlighting the contributions of service providers, along with the information on year of establishment, company size, location of headquarters, sources of antibodies and type of antibody (monoclonal, polyclonal and others), type of purification method (physio chemical, class specific and antigen affinity purification), application area (diagnostics, therapeutics and research) and end user (hospitals and clinics, industry and research institutes).
A company competitiveness analysis, highlighting prominent antibody purification service providers based in different regions, taking into consideration supplier strength (in terms of experience of a service provider), and portfolio specifications (sources of antibody, type of antibody, type of purification method and end user).
Elaborate profiles of antibody purification service providers. Each company profile features a brief overview of the company, antibody purification service portfolio and an informed future outlook.
An insightful regional capability assessment framework, which compares the capabilities of service providers (based on source of antibody, purification method and application area) across different regions.
Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
A case study on market landscape of companies, offering contract services for the manufacturing of antibodies, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies

One of the key objectives of the report was to estimate the existing market size and the future opportunities within the antibody purification services market. Based on multiple parameters, such as projected growth of overall antibody-based products market, cost of goods sold and direct manufacturing costs, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] company size (small, mid-sized and large / very large), [B] type of antibody (monoclonal, polyclonal and others), [C] type of purification method (physio chemical, class specific and antigen affinity purification), [D] end user (pharmaceutical and biotechnology companies, and diagnostic laboratories) and [E] key geographies (North America, Europe, Asia Pacific, Middle East, North Africa (MENA), Latin America (LATAM).
To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Who are the leading players offering antibody purification services?
What is the current geographical distribution of antibody purification service providers?
What are the common purification methods, end users and application areas offered by the service providers?
What are the key factors that are likely to influence the evolution of this market?
What is the likely demand in the antibody purification services domain?
How is the current and future opportunity likely to be distributed across key market segments?
What are the anticipated future trends in antibody purification services market?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the antibody purification services market in the mid to long term.

Chapter 3. In this chapter, we have briefly discussed the types of antibody purification methods. It highlights the need for outsourcing of antibody purification and the guidelines for selecting a service provider.

Chapter 4 provides an overview of the overall antibody purification services landscape, providing information on over 180 service providers that are currently active in this domain. It features an in-depth analysis of the market, based on year of establishment, company size, location of headquarters, sources of sources of antibodies and type of antibody (monoclonal, polyclonal and others), type of purification method (physio chemical, class specific and antigen affinity purification), application area (diagnostics, therapeutics and research) and end user (hospitals and clinics, industry and research institutes).

Chapter 5 provides an insightful competitiveness analysis of the antibody purification service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (experience of the service provider) and service portfolio strength (in terms of source of antibodies purified, type of antibody, type of purification method, application areas and end user).

Chapter 6 features detailed profiles of the key players active in the antibody purification services domain. Each company profile features a brief overview of the company, antibody purification service portfolio and an informed future outlook.

Chapter 7 chapter presents a detailed regional capability assessment framework which compares the capabilities of service providers (based on source of antibody, purification method and application area) across different regions.

Chapter 8 provides informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.

Chapter 9 presents a comprehensive market forecast analysis, highlighting the likely growth of antibody purification services market till the year 2030. The chapter provides likely distribution of the projected future opportunity based on company size (small, mid-sized and large / very large sized), type of antibody (monoclonal, polyclonal and others), type of purification method (physio chemical, class specific and antigen affinity purification), end user (hospitals and clinics, industry and research institutes) and key geographies (North America, Europe, Asia Pacific, MENA and LATAM).

Chapter 10 presents a detailed case study on market landscape of companies that offer contract services for manufacturing antibodies, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in the industry.

Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.
Read the full report: https://www.reportlinker.com/p06064559/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001